The goal of this activity is for learners to be better able to describe the efficacy and safety of an MRD-guided triple combination of venetoclax, zanubrutinib and obinutuzumab after an optional debulking with bendamustine, based on the primary endpoint analysis of the phase 2 CLL2-BZAG trial in 42 patients with relapsed/refractory CLL.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org
- Start Date: 2025-03-20 05:00:00
- End Date: 2025-03-20 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest